Cargando…

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

BACKGROUND AND AIMS: To report results from VISIBLE 2, a randomised, double-blind, placebo-controlled, phase 3 trial evaluating a new subcutaneous [SC] vedolizumab formulation as maintenance treatment in adults with moderately to severely active Crohn’s disease [CD]. METHODS: Following open-label ve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vermeire, Séverine, D’Haens, Geert, Baert, Filip, Danese, Silvio, Kobayashi, Taku, Loftus, Edward V, Bhatia, Siddharth, Agboton, Christian, Rosario, Maria, Chen, Chunlin, Zhang, Wenwen, Kisfalvi, Krisztina, Sandborn, William J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797168/ https://www.ncbi.nlm.nih.gov/pubmed/34402887 http://dx.doi.org/10.1093/ecco-jcc/jjab133

Ejemplares similares

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis
por: Vermeire, Séverine, et al.
Publicado: (2020)

Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease
por: Holmer, Ariela K., et al.
Publicado: (2020)

Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn’s Disease
por: Sandborn, William J, et al.
Publicado: (2021)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study
por: Reinisch, Walter, et al.
Publicado: (2020)

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial
por: Panés, Julian, et al.
Publicado: (2023)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme
por: Danese, Silvio, et al.
Publicado: (2020)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease
por: Dulai, Parambir S., et al.
Publicado: (2019)

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
por: Panés, Julian, et al.
Publicado: (2017)

Correction to: Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
Publicado: (2023)

Wound healing of metastatic perineal Crohn’s disease using hyperbaric oxygen therapy: A case series
por: Lansdorp, Corine A, et al.
Publicado: (2020)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Characterization of Mucosal Lesions in Crohn's Disease Scored With Capsule Endoscopy: A Systematic Review
por: Marquès Camí, Miquel, et al.
Publicado: (2021)

Vedolizumab in the treatment of Crohn’s disease of the pouch
por: Khan, Freeha, et al.
Publicado: (2018)

Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview
por: Pouillon, Lieven, et al.
Publicado: (2019)

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials
por: Panaccione, Remo, et al.
Publicado: (2018)

Efficacy of Vedolizumab in Fistulising Crohn’s Disease: Exploratory Analyses of Data from GEMINI 2
por: Feagan, Brian G, et al.
Publicado: (2018)

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis
por: Faleck, David M., et al.
Publicado: (2019)

A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
por: Panaccione, R, et al.
Publicado: (2022)

Vedolizumab for induction and maintenance of remission in Crohn's disease
por: Hui, Samuel, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study
por: Sandborn, William J, et al.
Publicado: (2021)

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry
por: Loftus, Edward V, et al.
Publicado: (2019)

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease
por: Lansdorp, Corine A., et al.
Publicado: (2020)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
por: Hébuterne, Xavier, et al.
Publicado: (2013)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

The Use of Vedolizumab in Patients with Concomitant Cirrhosis and Crohn’s Disease
por: Kapila, Nikhil, et al.
Publicado: (2018)

Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn’s Disease: Results from the EXTEND Trial
por: Reinisch, Walter, et al.
Publicado: (2017)

Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn’s Disease: Results from the Phase 2 HUBBLE Study
por: Hyams, Jeffrey S, et al.
Publicado: (2022)

Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program
por: Sandborn, William J., et al.
Publicado: (2020)

Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index
por: Bots, Steven, et al.
Publicado: (2021)

Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
por: Remy, Clotilde, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7a51hc72vq0jtacp3jjom7mjjo